RVL Pharmaceuticals plc Payment for Contingent Consideration Liability, Operating Activities
RVL Pharmaceuticals plc reported Payment for Contingent Consideration Liability, Operating Activities of $1.99 million for the 12-month period ending 2017-12-31, per its 8-K filed 2019-12-20.
Discontinued › Cash Flow › Operating Activities
us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities · last filed 2019-12-20
- RVL Pharmaceuticals plc payment for contingent consideration liability, operating activities for the quarter ending 2017-12-31 was $0.00.
| Period end | Payment for Contingent Consideration Liability, Operating Activities 3 month | Payment for Contingent Consideration Liability, Operating Activities 9 month | Payment for Contingent Consideration Liability, Operating Activities 12 month |
|---|---|---|---|
| 2017-12-31 | $0.00 derived: 8-K 12 month − 10-Q 9 month · filed 2019-12-20 | $1.99M 8-K · filed 2019-12-20 | |
| 2017-09-30 | $1.99M 10-Q · filed 2018-11-08 |